Michael Horowitz,[1,2,3] Tongzhi Wu,[1,3] Adam M. Deane,[1,3,4] Karen L. Jones,[1,3] and Christopher K. Rayner[1,3,5]

COMMENTARY

DPP-4 Inhibition and the Known Unknown

Science sometimes moves very slowly. Observations in 1964 (1,2) that the insulin response to oral (and enteral) glucose is substantially greater than that to an isoglycemic intravenous glucose infusion (the incretin effect), followed by characterization of the two known incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) (1973) and glucagon-like peptide 1 (GLP-1) (1985), have only recently led to the development of two classes of antidiabetes drugs, GLP-1 agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors, now used widely in the management of type 2 diabetes. GIP and GLP-1 are predominantly released from the proximal and distal intestine, respectively, primarily in response to enteral nutrients, and stimulate insulin secretion in a glucose-dependent manner (3). Attenuation of the incretin effect is probably an early marker of β-cell dysfunction (4). In type 2 diabetes, the incretin effect is markedly reduced (5), partly because the insulinotropic effect of GIP is essentially lost, whereas pharmacological doses of GLP-1 still stimulate insulin secretion substantially (6). GLP-1 also suppresses glucagon and slows gastric emptying (3,7).

Following their release, GLP-1 and GIP are rapidly degraded by the ubiquitous enzyme, DPP-4. The concept that inhibition of DPP-4 may represent a therapy for type 2 diabetes was expressed in a seminal article by Deacon et al. (8) in 1995. DPP-4 inhibition markedly increases circulating intact (active) GLP-1 and GIP concentrations. In 2006, the first DPP-4 inhibitor, sitagliptin, was approved by the U.S. Food and Drug Administration, and some 11 different DPP-4 inhibitors are now available worldwide. Their efficacy in reducing HbA_{1c} is comparable to other oral hypoglycemic drugs, but the risk of adverse effects, particularly hypoglycemia (because insulin stimulation is glucose dependent) and weight gain, is much less (3). It has been assumed that the increase in active GLP-1 accounts for glucose lowering by DPP-4 inhibition in type 2 diabetes—an assumption now shown to be only partly correct.

The elegant study by Nauck et al. (9) reported in this issue of *Diabetes* provides important insights regarding the mechanisms underlying glucose lowering by DPP-4 inhibition that are consistent with, and complimentary to, outcomes reported by Aulinger et al. (10) (Fig.1). In the study by Nauck et al. (9), a total of 32 patients with type 2 diabetes managed by diet or metformin and 29 healthy control subjects received vildagliptin 100 mg or placebo for 10 days in a crossover design. Meal tests, with concurrent assessment of gastric emptying, were performed on days 9 and 10, with and without intravenous exendin [9-39], a GLP-1 receptor antagonist. The primary end point was a modified insulinogenic index, i.e., the ratio of the insulin secretory response relative to plasma glucose, for 4 h postprandially. In patients with type 2 diabetes, insulinogenic indices (based on insulin, C-peptide, or insulin secretory rates) were increased by vildagliptin and reduced by exendin [9-39], but, importantly, the difference between these conditions was only ~50%. Hence, as concluded by Aulinger et al. (10) who evaluated the effects of sitagliptin, only about half of the insulinotropic effect of DPP-4 inhibition could be attributed to GLP-1. Exendin [9-39] also accelerated gastric emptying, whereas vildagliptin apparently had no effect. The original prespecified primary end point (glucagon) could, unfortunately, not be used because of cross-reactivity of exendin [9-39] in the immunoassay for glucagon. Although both Nauck et al. (9) and Aulinger et al. (10) evaluated the contribution of GLP-1 to the insulinotropic effect of DPP-4 inhibition, there were substantial differences in study design: *1*) different DPP-4 inhibitors were used, *2*) the duration of DPP-4 treatment differed from 2 to 9–10 days, *3*) the dose of exendin [9-39] used by Nauck et al. was lower, *4*) Nauck et al. studied a mixed meal rather than a 75-g glucose drink, and *5*) Nauck et al. included a control group without diabetes.

The studies performed by Aulinger et al. (10) and Nauck et al. (9) provide compelling evidence that GLP-1–dependent

[1]Discipline of Medicine, The University of Adelaide, Adelaide, Australia
[2]Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, Australia
[3]Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide, Australia
[4]Intensive Care Unit, Royal Adelaide Hospital, Adelaide, Australia
[5]Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, Australia

Corresponding author: Michael Horowitz, michael.horowitz@adelaide.edu.au.

Figure 1—Relative contribution of GLP-1–mediated vs. non-GLP-1–mediated mechanisms by which DPP-4 inhibitors lower glycemia, stimulate insulin, and suppress glucagon in patients with type 2 diabetes, studied after oral glucose (Aulinger et al. [10], using sitagliptin) or a mixed meal (Nauck et al. [9], using vildagliptin). For the study by Aulinger et al., these proportions have been calculated from mean data for incremental areas under the curve for blood glucose (240 min), insulin-to-glucose ratio (240 min), and glucagon (60 min), using the method proposed by the authors for the glucose-lowering effect. For the study by Nauck et al., the proportions are derived from the area under the curve for the insulin secretion rate–to–glucose ratio (240 min) as shown in their Fig. 2.

and –independent mechanisms are both important in glucose lowering by DPP-4 inhibitors, the latter represents the "known unknown." A potential confounder is that exendin [9-39] administered intravenously may incompletely antagonize intestinal GLP-1 receptors. In mice, inhibition of intestinal DPP-4 reduces plasma glucose without affecting plasma DPP-4 activity, GLP-1, or GIP (11). DPP-4 inhibition affects the degradation of other hormones; Nauck et al. (9) refer to four possibilities: GIP, oxyntomodulin, pituitary adenylate cyclase–activating peptide, and stromal cell–derived factor-1α. A role for GIP would not be surprising; in mice, DPP-4 inhibition reduces glycemia with targeted deletion of either, but not both, incretin receptors (12). Moreover, the insulinotropic response to GIP can be partially restored in patients with type 2 diabetes after a period of improved glycemic control (13), including that induced by a DPP-4 inhibitor (14). However, we observed a lack of glucose lowering by sitagliptin in patients with relatively well-controlled type 2 diabetes when glucose was infused intraduodenally at a rate sufficient to stimulate substantial GIP, but minimal GLP-1, secretion (15). Unfortunately, a specific GIP receptor antagonist is not available for use in humans.

Along with insulin secretion and sensitivity, gastric emptying, which exhibits substantial interindividual variation, is a major determinant of postprandial glycemia (16).

Studies using intraduodenal infusions of glucose indicate that GIP is the major contributor to the incretin effect in health when duodenal glucose delivery is ≤2 kcal/min and that GLP-1 assumes increasing importance at rates ≥3 kcal/min (17). In health and type 2 diabetes, the incretin effect is greater when glucose is delivered intraduodenally at 4 kcal/min compared with 2 kcal/min (18). Hence, the effect of DPP-4 inhibition on gastric emptying is of interest. Although Nauck et al. (9) found no effect measured by a breath test (9), there is probably a modest slowing (10,19), albeit much less than that induced by short-acting GLP-1 agonists (16). Gastric emptying is also a determinant of the glycemic response to DPP-4 inhibition (19,20), and strategies that slow gastric emptying and stimulate GLP-1 secretion, such as whey preloads (19), potentiate glucose lowering.

The studies of Nauck et al. (9) and Aulinger et al. (10) serve to remind the scientific community, including the pharma industry, that even for a specifically designed drug class such as DPP-4 inhibitors, mechanisms of action warrant careful scrutiny. In this way, "unknowns" can be resolved to provide therapeutic advances.

References

1.   Elrick H, Stimmler L, Hlad CJ Jr, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964;24:1076–1082

2.   McIntyre N, Holdsworth CD, Turner DS. New interpretation of oral glucose tolerance. Lancet 1964;2:20–21

3.   Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes Metab 2016;18:333–347

4.   Mari A, Bagger JI, Ferrannini E, Holst JJ, Knop FK, Vilsbøll T. Mechanisms of the incretin effect in subjects with normal glucose tolerance and patients with type 2 diabetes. PLoS One 2013;8:e73154

5.   Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46–52

6.   Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993;91:301–307

7.   Marathe CS, Rayner CK, Jones KL, Horowitz M. Relationships between gastric emptying, postprandial glycemia, and incretin hormones. Diabetes Care 2013;36:1396–1405

8.   Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995;44:1126–1131

9.   Nauck MA, Kind J, Köthe LD, et al. Quantification of the contribution of GLP-1 to mediating insulinotropic effects of DPP-4 inhibition with vildagliptin in healthy subjects and patients with type 2 diabetes using exendin [9-39] as a GLP-1 receptor antagonist. Diabetes 2016;65:2440–2447

10.   Aulinger BA, Bedorf A, Kutscherauer G, et al. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade. Diabetes 2014;63:1079–1092

11.   Waget A, Cabou C, Masseboeuf M, et al. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology 2011;152:3018–3029

12.   Hansotia T, Baggio LL, Delmeire D, et al. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 2004; 53:1326–1335

13.   Højberg PV, Vilsbøll T, Rabøl R, et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 2009;52:199–207

14.   Aaboe K, Akram S, Deacon CF, Holst JJ, Madsbad S, Krarup T. Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab 2015;17:74–81

15.   Wu T, Ma J, Bound MJ, et al. Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin. Diabetes 2014;63:2776–2787

16.   Phillips LK, Deane AM, Jones KL, Rayner CK, Horowitz M. Gastric emptying and glycaemia in health and diabetes mellitus. Nat Rev Endocrinol 2015;11:112–128

17.   Trahair LG, Horowitz M, Rayner CK, et al. Comparative effects of variations in duodenal glucose load on glycemic, insulinemic, and incretin responses in healthy young and older subjects. J Clin Endocrinol Metab 2012;97:844–851

18.   Marathe CS, Rayner CK, Bound M, et al. Small intestinal glucose exposure determines the magnitude of the incretin effect in health and type 2 diabetes. Diabetes 2014;63:2668–2675

19.   Wu T, Little TJ, Bound MJ, et al. A protein preload enhances the glucose-lowering efficacy of vildagliptin in type 2 diabetes. Diabetes Care 2016;39:511–517

20.   Stevens JE, Horowitz M, Deacon CF, Nauck M, Rayner CK, Jones KL. The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study. Aliment Pharmacol Ther 2012;36:379–390